OH2 Oncolytic Viral Therapy in Solid Tumors
A phase 1/2 trial of OH2 injection, with or without irinotecan or HX008 in advanced solid tumours, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.
Overview
OH2 Oncolytic Viral Therapy in Solid Tumors is a phase 1/2 interventional study registered as NCT03866525 by Binhui Biopharmaceutical Co., Ltd., with 300 participants planned, started 2019-04-02 and due to reach its primary completion in 2025-08-30. Interventions recorded: OH2 injection, with or without irinotecan or HX008.
Similar pages
not linked directly; found by shared links- TrialOH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors
Shares Binhui Biopharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialOH2 Injection in Melanoma
Shares Binhui Biopharmaceutical and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.